Cardiovascular conditions require individualised assessment
Patients experiencing nausea, vomiting, or diarrheacommon side effects, especially during dose initiation or escalationmay inadvertently decrease their consumption of both food and beverages while experiencing increased fluid losses, resulting in dehydration that manifests as oral dryness
Charges the immune system
Novo Nordisk says the US FDA has approved a once daily pill version of Wegovy, described as the first approved pill of its kind The company said trials showed average weight loss of 16.6%, with about a third of roughly 1,300 participants losing 20% or more Novo Nordisk expects a US launch in early January 2026, with investors pushing shares up sharply after the announcement amid strong competition in the weight loss market US regulators have approved an oral version of Wegovy for chronic weight management, giving Novo Nordisk the first daily pill in this drug class cleared for obesity treatment, according to the company and US media reports
For patients who benefit from dual-pathway activation, the GLP-Squared Injection combines semaglutide and tirzepatide in a single formulation starting at $289 monthly, while the GLP-Squared Oral version begins at $389/mo (or $369/mo on the 3-month plan)
